Sorafenib increases tumor hypoxia in cervical cancer patients treated with radiation therapy: results of a phase 1 clinical study
MF Milosevic, CA Townsley, N Chaudary… - International Journal of …, 2016 - Elsevier
Purpose Preclinical studies have shown that angiogenesis inhibition can improve response
to radiation therapy (RT). The purpose of this phase 1 study was to examine the
angiogenesis inhibitor sorafenib in patients with cervical cancer receiving radical RT and
concurrent cisplatin (RTCT). Methods and Materials Thirteen patients with stage IB to IIIB
cervical cancer participated. Sorafenib was administered daily for 7 days before the start of
standard RTCT in patients with early-stage, low-risk disease and also during RTCT in …
to radiation therapy (RT). The purpose of this phase 1 study was to examine the
angiogenesis inhibitor sorafenib in patients with cervical cancer receiving radical RT and
concurrent cisplatin (RTCT). Methods and Materials Thirteen patients with stage IB to IIIB
cervical cancer participated. Sorafenib was administered daily for 7 days before the start of
standard RTCT in patients with early-stage, low-risk disease and also during RTCT in …